The historical rank and industry rank for Emergent BioSolutions's FCF Margin % or its related term are showing as below:
STU:ER4'
s FCF Margin % Range Over the Past 10 Years
Min: -25.21 Med: 4.7 Max: 31.26
Current: 21.03
During the past 13 years, the highest FCF Margin % of Emergent BioSolutions was 31.26%. The lowest was -25.21%. And the median was 4.70%.
STU:ER4's FCF Margin % is ranked better than 89.87% of 958
companies
in the Drug Manufacturers industry
Industry Median: 2.445
vs STU:ER4: 21.03
Emergent BioSolutions FCF Margin % Related Terms
Emergent BioSolutions FCF Margin % Historical Data
* Premium members only.
The historical data trend for Emergent BioSolutions's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:ER4 vs AQST, EOLS, ELTP: FCF Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Emergent BioSolutions's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Emergent BioSolutions FCF Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Emergent BioSolutions's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Emergent BioSolutions's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Emergent BioSolutions (STU:ER4) has a FCF Margin % of -24.18% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Emergent BioSolutions and its competitors. According to the industry distribution chart, Emergent BioSolutions ranks #97 out of 958 companies in the Drug Manufacturers industry, placing it in the top 10.1%.
Is Emergent BioSolutions' FCF Margin % too high?
Emergent BioSolutions' current FCF Margin % is -24.18%. Based on the distribution chart, Emergent BioSolutions ranks #97 out of 958 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Emergent BioSolutions has a GF Score™ of 51/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Emergent BioSolutions' FCF Margin % compare to AQST and EOLS?
According to the Drug Manufacturers industry distribution chart, Emergent BioSolutions ranks #97 out of 958 companies for FCF Margin %. This places Emergent BioSolutions in the top 10% of its industry — outperforming the majority of peers. The industry median FCF Margin % is 2.45. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Drug Manufacturers company?
The median FCF Margin % among Drug Manufacturers companies is 2.45, based on 958 companies in the industry. Companies in the top quartile (top 25%) have a FCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Emergent BioSolutions and its competitors. For the Drug Manufacturers industry, the median FCF Margin % is 2.45 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Emergent BioSolutions's current FCF Margin % is -24.18%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Emergent BioSolutions stock overvalued right now?
Based on GuruFocus' analysis, Emergent BioSolutions (STU:ER4) is currently considered Significantly Overvalued. The stock's GF Value™ is €4.05, compared to a current price of €7.34 — trading 81.1% above its estimated fair value. The current FCF Margin % is -24.18%. Emergent BioSolutions' overall GF Score™ is 51/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Emergent BioSolutions (STU:ER4), the current FCF Margin % is -24.18% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Emergent BioSolutions (STU:ER4) Overvalued in 2026?
Based on GuruFocus' analysis, Emergent BioSolutions stock appears to be overvalued.
The current stock price of €7.34 is trading 81.1% above its estimated GF Value™ of €4.05.
GuruFocus considers Emergent BioSolutions to be Significantly Overvalued.
Key valuation signals for STU:ER4:
FCF Margin %: -24.18%
GF Value™: €4.05 vs. price of €7.34 (81.1% above fair value)
No single metric tells the full story. See the STU:ER4 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Emergent BioSolutions Inc offers public health products to the government and healthcare providers. Company operates in three segments namely Commercial Product, MCM Products, and Services segment. The Commercial Product Segment consisting of Nasal Spray; the MCM Products Segment consisting of Anthrax-MCM products, Smallpox-MCM products and Other Products and the Services Segment consisting of Bioservices portfolio. Geographically, the company operates in United States, Canada, and Others. It derives maximum revenue from United states. The company's products include: NARCAN Nasal Spray, KLOXXADO Nasal Spray, ACAM2000, ANTHRASIL, BAT, BioThrax, CNJ-016, raxibacumab injection, Ebanga, and others.
51GF Score
Get the complete analysis for STU:ER4
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:ER4 has been successfully added to your 
